COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
TxCell is a France-based biotechnology company developing antigen-specific regulatory T cell (Treg) therapies, including Ovasave for treatment-refractory Crohn’s disease, with completed Phase I/II clinical evaluation.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors